Pfizer (incl. Seagen)

Enfortumab vedotin is an ADC against Nectin-4 that, combined with pembrolizumab, nearly doubled survival in advanced bladder cancer.

The ADC that made the modern field credible (2011), for Hodgkin lymphoma and CD30+ lymphomas.

Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.

A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases.

Disitamab vedotin is a Chinese HER2 ADC approved for gastric and bladder cancer, now in global trials with Pfizer.

Palbociclib was the first CDK4/6 inhibitor (2015), and in 2026 became the first approved as maintenance in HER2-positive, hormone-positive breast cancer.

An ALK inhibitor with the longest disease control ever recorded for a targeted lung cancer pill: 60% progression-free at five years.

Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026.

Talazoparib is a PARP inhibitor that traps PARP on DNA about 100 times more strongly than olaparib, which is why it works at a 1 mg daily dose. It is approved for germline BRCA-mutant HER2-negative breast cancer and, with enzalutamide, for HRR-mutant castration-resistant prostate cancer; anaemia is its dominant side effect.

Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations.

Gemtuzumab ozogamicin (Mylotarg) is an anti-CD33 antibody linked to the DNA-cutting payload calicheamicin, the first ADC approved, in 2000 for relapsed acute myeloid leukaemia. An unstable linker and no benefit in a confirmatory trial led to withdrawal in 2010; it returned in 2017 at a lower fractionated dose, with liver toxicity, including veno-occlusive disease, its defining risk.

PF-08634404 is an experimental investigational agent whose form is not stated in the registry from Pfizer in phase 3 trials for colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer, with its target not yet stated publicly.

PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.

Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.

PF-08046054 is an experimental antibody-drug conjugate from Pfizer in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.

Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer.

Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.

Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.

Exemestane is a steroidal aromatase inhibitor, the partner of everolimus and the agent tested with ovarian suppression in young women.

Estramustine is an oral prostate cancer drug that combines an oestrogen with an alkylating agent, approved in the United States in 1981 for metastatic disease and later combined with taxanes, though its clotting risk has pushed it out of routine use.

Dexrazoxane protects the heart from the cumulative damage of doxorubicin in women with metastatic breast cancer who need to keep receiving it, and, as Totect, limits tissue destruction when an anthracycline leaks out of a vein.

Oprelvekin was the first drug approved, in 1997, to prevent the severe platelet falls that chemotherapy causes, but fluid retention and heart rhythm problems limited it and it was withdrawn in 2011; thrombopoietin agonists took over the problem.

A next-generation pill that blocks only CDK4, not CDK6, to keep the benefit of today's drugs without the low blood counts.

Avelumab is a PD-L1 blocker given as maintenance after chemotherapy for advanced bladder cancer, which lengthened survival by about seven months.

Axitinib is a selective VEGF-receptor pill, now given mainly with pembrolizumab or avelumab as first-line kidney cancer treatment.

Binimetinib is the MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.

Bosutinib is a CML pill with less cardiovascular and pleural toxicity than its rivals; its main side effect is diarrhoea.

Cabergoline is a tablet taken once or twice a week that shrinks prolactin-secreting pituitary tumours and normalises hormone levels in most patients, so surgery is reserved for the few whose tumours resist or who cannot tolerate it.

Celecoxib is a common anti-inflammatory painkiller. In oncology it is paired with low-dose oral methotrexate as a cheap 'metronomic' treatment for advanced head and neck cancer, a regimen from Tata Memorial in Mumbai that beat intravenous cisplatin in a randomised trial.

Crizotinib was the first ALK inhibitor, approved four years after ALK fusions were found in lung cancer; it was also the first drug for ROS1 lung cancer and for ALK-positive lymphoma and inflammatory myofibroblastic tumour in children.

A second-generation EGFR pill that beat gefitinib on survival in EGFR-mutant lung cancer but was quickly overshadowed by osimertinib.

Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.

Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-resistant disease, and fatigue, falls and memory problems are its main drawbacks.

Epirubicin (Ellence) is a close relative of doxorubicin used mainly after breast cancer surgery when lymph nodes are involved, and in stomach cancer regimens; it is a little kinder to the heart.

Epoetin alfa is a manufactured version of the kidney hormone that tells the bone marrow to make red blood cells. In cancer it treats anaemia caused by chemotherapy and reduces the need for transfusions, but it is used cautiously because it can shorten survival and cause clots.

Glasdegib is a hedgehog-pathway pill that, with low-dose chemotherapy, extends survival in older AML patients who cannot have intensive treatment; it has largely been displaced by venetoclax combinations.

Idarubicin is an anthracycline chemotherapy approved in 1990 for adult acute myeloid leukaemia, given with cytarabine in 3+7 induction and FLAG-Ida salvage and in acute promyelocytic leukaemia protocols. Randomised trials showed more complete remissions than with daunorubicin, which is why centres prefer it; heart damage, marrow suppression and extravasation injury are the class risks.

Inotuzumab ozogamicin is an antibody carrying a DNA-cutting toxin to CD22 on leukaemia cells. It gets far more relapsed ALL patients into remission than chemotherapy and bridges them to transplant.

Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.

An epigenetic drug that may re-sensitise prostate cancer to hormone therapy, in three phase 3 trials with enzalutamide.

Pegvisomant is a daily injection that blocks growth hormone at its receptor. It normalises the downstream hormone IGF-1 in most people with acromegaly whose tumours were not cured by surgery, although it does not shrink the tumour itself.

Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.

A weekly infusion that was the first drug to extend survival in poor-risk kidney cancer (2007), and in 2024 the first targeted drug to improve outcomes in childhood rhabdomyosarcoma.